Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).
复制标题
DOI：
10.1016/j.jtct.2022.09.002
复制
发表时间：
2022-12
影响因子：
3.2
通讯作者：
Papanicolaou, Genovefa A.
中科院分区：
文献类型：
--
作者：
Dioverti, Veronica;El Boghdadly, Zeinab;Shahid, Zainab;Waghmare, Alpana;Abidi, Maheen Z.;Pergam, Steven;Boeckh, Michael;Dadwal, Sanjeet;Kamboj, Mini;Seo, Susan;Chemaly, Roy F.;Papanicolaou, Genovefa A.
本文件旨在作为成人和儿童HCT和细胞治疗患者中由SARS-CoV-2病毒引起的2019冠状病毒病（COVID-19）的诊断和管理指南。本文件是根据现有数据和（ASTCT）传染病特别兴趣小组（ID-SIG）成员提供的专家意见编写的，是对以前出版物的更新。自我们在2020年最初发表以来，NIH和IDSA已经发布了广泛的COVID-19管理指南，这些指南很容易获得（NIH指南，IDSA指南）。本更新主要关注与HCT/细胞治疗接受者相关的问题。本手稿中提供的信息可能会随着新信息的出现而改变。
This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.
登录
查看更多内容
影响因子：
20.3
作者：
Dhakal B;Abedin S;Fenske T;Chhabra S;Ledeboer N;Hari P;Hamadani M
通讯作者：
Hamadani M
DOI：
10.3390/curroncol29010030
发表时间：
2022-01-13
期刊：
Current oncology (Toronto, Ont.)
影响因子：
--
作者：
Bailey AJM;Kirkham AM;Monaghan M;Shorr R;Buchan CA;Bredeson C;Allan DS
通讯作者：
Allan DS
影响因子：
7.4
作者：
Blot M;Bour JB;Quenot JP;Bourredjem A;Nguyen M;Guy J;Monier S;Georges M;Large A;Dargent A;Guilhem A;Mouries-Martin S;Barben J;Bouhemad B;Charles PE;Chavanet P;Binquet C;Piroth L;LYMPHONIE study group
通讯作者：
LYMPHONIE study group
影响因子：
3.9
作者：
Colson P;Devaux CA;Lagier JC;Gautret P;Raoult D
通讯作者：
Raoult D
影响因子：
16.6
作者：
Buckland MS;Galloway JB;Fhogartaigh CN;Meredith L;Provine NM;Bloor S;Ogbe A;Zelek WM;Smielewska A;Yakovleva A;Mann T;Bergamaschi L;Turner L;Mescia F;Toonen EJM;Hackstein CP;Akther HD;Vieira VA;Ceron-Gutierrez L;Periselneris J;Kiani-Alikhan S;Grigoriadou S;Vaghela D;Lear SE;Török ME;Hamilton WL;Stockton J;Quick J;Nelson P;Hunter M;Coulter TI;Devlin L;CITIID-NIHR COVID-19 BioResource Collaboration;MRC-Toxicology Unit COVID-19 Consortium;Bradley JR;Smith KGC;Ouwehand WH;Estcourt L;Harvala H;Roberts DJ;Wilkinson IB;Screaton N;Loman N;Doffinger R;Lyons PA;Morgan BP;Goodfellow IG;Klenerman P;Lehner PJ;Matheson NJ;Thaventhiran JED
通讯作者：
Thaventhiran JED